Pharmacogenomic Testing for Antidepressants Could Save Time, Money

A model showed that pharmacogenomic testing of patients with newly diagnosed major depressive disorder could save the health system $956 million CAD over 20 years.

Related Keywords

United Kingdom ,Calgary ,Alberta ,Canada ,Canadian ,British ,Canadians ,Shahzad Ghanbarian ,Canadian Medical Association Journal ,World Health Organization ,Clinical Pharmacogenetics Implementation Consortium ,University Of Calgary ,British Columbia ,Clinical Epidemiology ,Medscape Medical ,Canadian Medical Association ,Depression ,Genomics ,Genomic Medicine ,Edicine Genomic ,Cost Effectiveness Research ,Cost Benefit Analysis ,Pharmacogenomics ,Personalized Medicine ,Major Depression ,Major Depressive Disorder ,Nipolar Depression ,Antidepressant ,Antidepressant Drug ,Rug Antidepressant , ,Refractory ,Patient Safety ,Adverse Effects ,Side Effects ,Genetics ,Health Care Economics ,Conomics ,